Johnson & Johnson’s 4Q profit rises 19 percent

Published



Surging sales of Johnson & Johnson’s prescription medicines and the rebound of its recall-plagued consumer health business lifted fourth-quarter profit 19 percent.

The health care giant also enjoyed a $707 million tax benefit from writing off money-losing subsidiary Scios.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.